A new finding, not commonly reported in the subcutaneous semaglutide clinical trial program, was dysesthesia
Patients with MS often experience comorbidities including metabolic syndrome, type 2 diabetes, and obesity, which may be exacerbated by reduced mobility and certain treatments, particularly corticosteroids used for acute relapses
Key Takeaways Diarrhea is a common gastrointestinal side effect of semaglutide, especially as the medication alters how quickly food moves through the digestive system
What happens in your body after the first GLP-1 dose The moment a GLP-1 receptor agonist enters your bloodstream, a cascade begins
Patients who lose 80, 90, 100 pounds or more
If energy consistently drops below 5, your diet likely needs adjustment, either more calories, more protein, or addressing a specific nutrient deficiency